Search
01/05/2024
Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients
Escate, R, Padró, T, de Isla, LP, Fuentes, F, Alonso, R, Mata, P, Badimon, L. Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients. ATHEROSCLEROSIS. 2024; 392DOI:10.1016/j.atherosclerosis.2024.117502. PMID:38513437. IF:5.700(Q1/1D).
01/05/2024
Lysyl Oxidase in Ectopic Cardiovascular Calcification: Role of Oxidative Stress
Ballester-Servera, C, Alonso, J, Cañes, L, Vázquez-Sufuentes, P, García-Redondo, AB, Rodríguez, C, Martínez-González, J. Lysyl Oxidase in Ectopic Cardiovascular Calcification: Role of Oxidative Stress. Antioxidants. 2024; 13(5)DOI:10.3390/antiox13050523. PMID:38790628. IF:6.600(Q1/1D).
01/05/2024
Insulin glargine 300 U/ml versus insulin degludec 100 U/ml improves nocturnal glycaemic control and variability in type 1 diabetes under routine clinical practice: A glucodensities-based post hoc analysis of the OneCare study
Gomez-Peralta, F, Ballesteros, AC, Martínez, AM, Corral, BP, Donlo, IC, Melo, PF, Arnáez, FZ, Rodríguez, MM. Insulin glargine 300 U/ml versus insulin degludec 100 U/ml improves nocturnal glycaemic control and variability in type 1 diabetes under routine clinical practice: A glucodensities-based post hoc analysis of the OneCare study. DIABETES OBESITY & METABOLISM. 2024; 26(5)DOI:10.1111/dom.15496. PMID:38379106. IF:5.700(Q1/2D).
01/05/2024
A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting Response
Beato-Vibora, PI, Chico, A, Moreno-Fernandez, J, Bellido-Castañeda, V, Nattero-Chávez, L, Picón-César, MJ, Martínez-Brocca, MA, Gimenez-Alvarez, M, Aguilera-Hurtado, E, Climent-Biescas, E, Azriel-Mira, S, Rebollo-Román, A, Yoldi-Vergara, C, Pazos-Couselo, M, Alonso-Carril, N, Quirós, C. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting Response. DIABETES CARE. 2024; 47(5)DOI:10.2337/dci24-0017. PMID:38640410. IF:16.600(Q1/1D).
01/05/2024
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Garcia, MJ, Riestra, S, Amiot, A, Julsgaard, M, de la Filia, IG, Calafat, M, Aguas, M, de la Pena, L, Roig, C, Caballol, B, Casanova, MJ, Farkas, K, Boysen, T, Bujanda, L, Cuaran, C, Dobru, D, Fousekis, F, Gargallo-Puyuelo, CJ, Savarino, E, Calvet, X, Huguet, JM, Kupcinskas, L, López-Cardona, J, Raine, T, van Oostrom, J, Gisbert, JP, Chaparro, M. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study). ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 59(10)DOI:10.1111/apt.17938. PMID:38445785. IF:6.700(Q1/1D).
01/05/2024
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Gómez-Labrador, C, Ricart, E, Iborra, M, Iglesias, E, Martín-Arranz, MD, de Castro, L, De Francisco, R, García-Alonso, FJ, Sanahuja, A, Gargallo-Puyuelo, CJ, Mesonero, F, Casanova, MJ, Mañosa, M, Rivero, M, Calvo, M, Sierra-Ausin, M, González-Muñoza, C, Calvet, X, García-López, S, Guardiola, J, García, LA, Márquez-Mosquera, L, Gutiérrez, A, Zabana, Y, Navarro-Llavat, M, Poyatos, RL, Piqueras, M, Torrealba, L, Bermejo, F, Ponferrada-Díaz, A, Pérez-Calle, JL, Barreiro-de Acosta, M, Tejido, C, Cabriada, JL, Marín-Jiménez, I, Roncero, O, Ber, Y, Fernández-Salazar, L, Aler, BC, Lucendo, AJ, Llaó, J, Bujanda, L, Villafranca, CM, Domènech, E, Chaparro, M, Gisbert, JP. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA. Pharmaceutics. 2024; 16(5)DOI:10.3390/pharmaceutics16050629. PMID:38794292. IF:5.500(Q1/1D).